Iftekhar Mahmood

Dr. Iftekhar Mahmood

Mahmood clinical pharmacology consultancy, LLC

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 October 2009 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Iftekhar MahmoodIftekhar Mahmood
Iftekhar Mahmood

1 July 2010 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Iftekhar MahmoodIftekhar Mahmood
Iftekhar Mahmood

1 December 2007 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Iftekhar MahmoodIftekhar Mahmood
Iftekhar Mahmood
MGMarti Davi. Green
Marti Davi. Green

21 May 2021 in Antibodies
Verified
Journal Article
Open access
PDF file
Iftekhar MahmoodIftekhar Mahmood
Iftekhar Mahmood
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogenous leukemia, several ADCs have been developed for the treatment of cancer. The goal of an ADC as a cancer agent is to release the cytotoxic drug to kill the tumor cells without harming the normal or healthy cells. With time, it is being realized that ADCS can also be used to manage or cure other diseases such as inflammatory diseases, atherosclerosis, and bacteremia and some research in this direction is ongoing. The focus of this review is on the clinical pharmacology aspects of ADC development. From the selection of an appropriate antibody to the finished product, the entire process of the development of an ADC is a difficult and challenging task. Clinical pharmacology is one of the most important tools of drug development since this tool helps in finding the optimum dose of a product, thus preserving the safety and efficacy of the product in a patient population. Unlike other small or large molecules where only one moiety and/or metabolite(s) is generally measured for the pharmacokinetic profiling, there are several moieties that need to be measured for characterizing the PK profiles of an ADC. Therefore, knowledge and understanding of clinical pharmacology of ADCs is vital for the selection of a safe and efficacious dose in a patient population.